A study published in the Clinical Kidney Journal found no significant differences in all-cause or cardiovascular mortality between patients undergoing hemodialysis with a prescription of dialysate calcium at 1.50 versus 1.25 mmol/L. The research, which included over 12,000 patients, indicated that while there was a higher unadjusted risk for all-cause mortality with the higher dosage, when adjusting for other factors, no significant differences were observed. The study also found that sudden cardiac death risk was lower with the higher calcium dosage. This supports the recommendation that dialysate calcium prescription should be based on individual patient characteristics.
Source link
Varying dialysate calcium dosage not tied to differences in all-cause, cardiovascular mortality
